In our cohort, 67 (24.63%) ALN FNA+ breast cancer patients were recommended to receive neoadjuvant chemotherapy: 29 (43.28%) patients with HER2+ breast cancer and 7 (10.45%) patients with TNBC. Here, ERBB2 is linked to breast carcinoma.